SCHEMBL580901

SCHEMBL580901

Oc1ccc(Cc2nnc(-c3ccccc3)c3ccccc23)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 7/20 0.49
HTT P42858 3/20 0.48
LMNA P02545 1/20 0.48
PRNP P04156 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
PPARG P37231 1/20 0.48
NCOA2 Q15596 1/20 0.48
RXFP1 Q9HBX9 1/20 0.48
MET P08581 3/20 0.47
GAA P10253 1/20 0.47
MAPT P10636 4/20 0.44
PDGFRB P09619 2/20 0.43
FLT1 P17948 2/20 0.43
KDR P35968 2/20 0.43
KIT P10721 1/20 0.43
ALDH1A1 P00352 2/20 0.43
ATM Q13315 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10217412 0.83 FLT1 (0.60) NPSR1HTTLMNAPRNPCYP1A2
SCHEMBL580885 0.81 KDR (0.62) NPSR1HTTLMNAMAPTKDR
SCHEMBL10217415 0.78 MEN1 (0.47) NPSR1HTTLMNAPRNPCYP1A2
SCHEMBL28139644 0.77 GAA (0.68) NPSR1HTTLMNACYP1A2CYP2C9
SCHEMBL10217403 0.76 MEN1 (0.61) NPSR1HTTLMNAPRNPCYP1A2
SCHEMBL4864061 0.73 HTT (0.60) NPSR1HTTLMNACYP1A2CYP3A4
SCHEMBL24733360 0.73 NPSR1 (0.56) NPSR1HTTLMNAPRNPCYP1A2
SCHEMBL15761431 0.72 PDE4A (0.41) NPSR1HTTLMNAPRNPCYP1A2
SCHEMBL13911024 0.71 HTT (0.54) NPSR1HTTLMNACYP1A2CYP3A4
Biphenyl SCHEMBL8082690 0.71 ESR1 (0.70) HTTLMNACYP3A4METGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9242961-B2 Aurora kinase modulators and method of use AMGEN INC. (US) 2016-01-26 US disclosed
US-9242961-B2 Aurora kinase modulators and method of use AMGEN INC. (US) 2016-01-26 US disclosed
US-9242961-B2 Aurora kinase modulators and method of use AMGEN INC. (US) 2016-01-26 US disclosed
EP-1984353-B1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC (US) 2015-12-30 EP disclosed
EP-1984353-B1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC (US) 2015-12-30 EP disclosed
EP-2418209-B1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC (US) 2014-06-25 EP disclosed
EP-2418209-B1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC (US) 2014-06-25 EP disclosed
US-20140066430-A1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC. (US) 2014-03-06 US disclosed
US-20140066430-A1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC. (US) 2014-03-06 US disclosed
US-20140066430-A1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC. (US) 2014-03-06 US disclosed
US-20090163501-A1 Aurora kinase modulators and method of use AMGEN INC. (US) 2009-06-25 US disclosed
US-20090163501-A1 Aurora kinase modulators and method of use AMGEN INC. (US) 2009-06-25 US disclosed
US-20090163501-A1 Aurora kinase modulators and method of use AMGEN INC. (US) 2009-06-25 US disclosed
CN-101405282-A Aurora kinase modulators and methods of use AMGEN INC (US) 2009-04-08 CN disclosed
EP-1984353-A1 AURORA KINASE MODULATORS AND METHOD OF USE Amgen, Inc (US) 2008-10-29 EP disclosed
US-20070185111-A1 Aurora kinase modulators and method of use AMGEN INC. 2007-08-09 US disclosed
US-20070185111-A1 Aurora kinase modulators and method of use AMGEN INC. 2007-08-09 US disclosed
US-20070185111-A1 Aurora kinase modulators and method of use AMGEN INC. 2007-08-09 US disclosed
WO-2007087276-A1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC. (US) 2007-08-02 WO disclosed
WO-2007087276-A1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC. (US) 2007-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140066430-A1 AURORA KINASE MODULATORS AND METHOD OF USE AURKC, AURKA, AURKB NPSR1 3589/4885HTT 4451/4885LMNA 620/4885
US-20070185111-A1 Aurora kinase modulators and method of use AURKC, AURKA, CDK1 NPSR1 3001/4885HTT 4681/4885LMNA 637/4885
US-20090163501-A1 Aurora kinase modulators and method of use AURKC, AURKA, AURKB NPSR1 3589/4885HTT 4451/4885LMNA 620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.